S&P 500   2,736.86 (+2.91%)
DOW   23,296.97 (+2.84%)
QQQ   199.84 (+1.75%)
AAPL   265.39 (+2.30%)
FB   173.75 (+2.91%)
MSFT   164.68 (+0.73%)
GOOGL   1,207.80 (+2.13%)
AMZN   2,037.34 (+1.35%)
NVDA   266.34 (+2.82%)
BABA   195.34 (-1.34%)
MU   48.31 (+3.80%)
GE   7.27 (+3.27%)
TSLA   544.62 (-0.15%)
AMD   48.66 (+2.31%)
T   29.78 (-1.00%)
ACB   0.86 (+7.51%)
F   5.00 (+6.16%)
NFLX   369.26 (-0.81%)
BAC   23.27 (+5.06%)
DIS   100.41 (-0.82%)
PRI   97.00 (+10.15%)
S&P 500   2,736.86 (+2.91%)
DOW   23,296.97 (+2.84%)
QQQ   199.84 (+1.75%)
AAPL   265.39 (+2.30%)
FB   173.75 (+2.91%)
MSFT   164.68 (+0.73%)
GOOGL   1,207.80 (+2.13%)
AMZN   2,037.34 (+1.35%)
NVDA   266.34 (+2.82%)
BABA   195.34 (-1.34%)
MU   48.31 (+3.80%)
GE   7.27 (+3.27%)
TSLA   544.62 (-0.15%)
AMD   48.66 (+2.31%)
T   29.78 (-1.00%)
ACB   0.86 (+7.51%)
F   5.00 (+6.16%)
NFLX   369.26 (-0.81%)
BAC   23.27 (+5.06%)
DIS   100.41 (-0.82%)
PRI   97.00 (+10.15%)
S&P 500   2,736.86 (+2.91%)
DOW   23,296.97 (+2.84%)
QQQ   199.84 (+1.75%)
AAPL   265.39 (+2.30%)
FB   173.75 (+2.91%)
MSFT   164.68 (+0.73%)
GOOGL   1,207.80 (+2.13%)
AMZN   2,037.34 (+1.35%)
NVDA   266.34 (+2.82%)
BABA   195.34 (-1.34%)
MU   48.31 (+3.80%)
GE   7.27 (+3.27%)
TSLA   544.62 (-0.15%)
AMD   48.66 (+2.31%)
T   29.78 (-1.00%)
ACB   0.86 (+7.51%)
F   5.00 (+6.16%)
NFLX   369.26 (-0.81%)
BAC   23.27 (+5.06%)
DIS   100.41 (-0.82%)
PRI   97.00 (+10.15%)
S&P 500   2,736.86 (+2.91%)
DOW   23,296.97 (+2.84%)
QQQ   199.84 (+1.75%)
AAPL   265.39 (+2.30%)
FB   173.75 (+2.91%)
MSFT   164.68 (+0.73%)
GOOGL   1,207.80 (+2.13%)
AMZN   2,037.34 (+1.35%)
NVDA   266.34 (+2.82%)
BABA   195.34 (-1.34%)
MU   48.31 (+3.80%)
GE   7.27 (+3.27%)
TSLA   544.62 (-0.15%)
AMD   48.66 (+2.31%)
T   29.78 (-1.00%)
ACB   0.86 (+7.51%)
F   5.00 (+6.16%)
NFLX   369.26 (-0.81%)
BAC   23.27 (+5.06%)
DIS   100.41 (-0.82%)
PRI   97.00 (+10.15%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Axovant Gene TherapiesProteostasis TherapeuticsEnlivex TherapeuticsVaccinexTrevi Therapeutics
SymbolNASDAQ:AXGTNASDAQ:PTINASDAQ:ENLVNASDAQ:VCNXNASDAQ:TRVI
Price Information
Current Price$2.64$1.16$4.50$3.88$2.64
52 Week RangeBuyBuyBuyN/ABuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$18.50$5.33$22.00N/A$16.75
% Upside from Price Target600.76% upside359.77% upside388.89% upsideN/A534.47% upside
Trade Information
Market Cap$95.74 million$59.45 million$54.97 million$63.38 million$48.15 million
Beta1.260.991.91.68N/A
Average Volume229,3371,538,645137,87029,55766,329
Sales & Book Value
Annual RevenueN/A$5 millionN/A$520,000.00N/A
Price / SalesN/A12.10N/A121.88N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.47 per share$1.22 per share$21.98 per share($0.15) per share$3.06 per share
Price / BookN/A0.95N/A-25.83N/A
Profitability
Net Income$-129,070,000.00$-59,130,000.00$-4,240,000.00$-31,860,000.00$-26,050,000.00
EPS($8.02)($1.16)($1.40)($2.47)($2.28)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-4,740.03%N/A
Return on Equity (ROE)-241.62%-74.97%N/A-2,277.96%-154.41%
Return on Assets (ROA)-75.95%-57.97%N/A-355.72%-47.73%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.28%0.19%N/AN/AN/A
Current Ratio1.09%6.88%3.97%0.58%11.45%
Quick Ratio1.09%6.88%3.97%0.58%11.45%
Ownership Information
Institutional Ownership Percentage7.17%21.73%0.71%9.09%79.53%
Insider Ownership Percentage5.50%19.80%N/A69.90%N/A
Miscellaneous
Employees4548314415
Shares Outstanding36.82 million52.15 million11.33 million16.36 million17.84 million
Next Earnings Date6/9/2020 (Estimated)5/13/2020 (Estimated)5/18/2020 (Estimated)5/20/2020 (Estimated)6/15/2020 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel